



FACT SHEET: MALLINCKRODT PHARMACEUTICALS DONATES 10,000 MEDICATION DEACTIVATION POUCHES FOR SAFE MEDICATION DISPOSAL IN COOPERSTOWN, N.Y., AREA COMMUNITIES

WHAT:

- Mallinckrodt Pharmaceuticals has purchased and donated 10,000 medication deactivation pouches¹ to help support safe communities in the Cooperstown area and prevent prescription opioid abuse, misuse and diversion. The donation of 10,000 pouches was made to LEAF Council on Alcoholism and Addictions with Bassett Healthcare Network assisting in the distribution.
- The medication deactivation pouches were purchased and donated by Mallinckrodt, a leading global specialty pharmaceutical company, as part of the company's nationwide strategy and commitment to address the complex issues of prescription drug abuse.

DONATION HELPS COMBAT URGENT PUBLIC HEALTH ISSUE:

- The abuse and misuse of opioids frequently begins with prescription pills found in the home.
- A national survey of U.S. adults who used opioids showed that nearly 6 out of 10 had or expect to have leftover opioids (June 13, 2016, online *JAMA Internal Medicine* journal).
- Nearly 68 percent of those who used prescription pain relievers non-medically in 2012-2013 got them from friends or relatives (2013 *Substance Abuse and Mental Health Services Administration National Survey on Drug Use and Health*).

HOW THE POUCH WORKS:

- The user-friendly pouch deactivates prescription drugs and renders contents safe for landfills.
- After filling the specially formulated pouch with regular tap water, it can be sealed and thrown away with the household trash, rendered safe for landfills.
- It is possible that 450,000 pills could be destroyed if each of the 10,000 pouches is used to its 45-pills capacity.

ABOUT MALLINCKRODT'S COMMITMENT TO PATIENTS AND COMMUNITIES:

- The initiative reinforces Mallinckrodt's long-standing commitment to the safe and responsible use of medications and its collaboration with community leaders who share the goal of building public awareness of responsible drug disposal's critical role in the fight against prescription drug abuse. Find more information at www.mallinckrodt.com/disposal.
- Mallinckrodt has a long history of strongly advocating for addressing the complex issues of opioid misuse and abuse, and believes that providing a safe, environmentally responsible way to dispose of unused medications is crucial in this fight against prescription drug abuse.
- The pouch donation initiative is one part of Mallinckrodt's comprehensive approach that includes:
 - Investing in and expanding the use of opioid abuse-deterrent technology. The company supports development of tamper-resistant/abuse-deterrent technologies and regulatory standards that support the adoption of these technologies.
 - Being a vocal advocate for a prescription drug-monitoring program (PDMP) in Missouri and supports improving integration of federal and state PDMPs.

¹ Drug deactivation pouch systems are manufactured by Minneapolis-based Verde Technologies.



- Developing and sharing best practices for monitoring suspicious orders, both at the manufacturing and supply chain stages.
- Improving stakeholder education for patients, providers and the public at large, and enhancing drug take-back and addiction rehabilitation programs
- Mallinckrodt is dedicated to working with policy makers, community leaders, law enforcement and industry partners to ensure the responsible use of pain medications and prevent unused medications from ending up in the wrong hands.

ABOUT MALLINCKRODT

Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and therapies, as well as nuclear imaging products. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and hemostasis products; and central nervous system drugs. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the Nuclear Imaging segment includes nuclear imaging agents. To learn more about Mallinckrodt, visit www.mallinckrodt.com.